PDL BioPharma, Inc. (NASDAQ:PDLI)

CAPS Rating: 4 out of 5

A biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for severe or life-threatening illnesses.

Recs

0
Player Avatar eesirrius (< 20) Submitted: 7/15/2011 10:24:57 AM : Outperform Start Price: $5.81 PDLI Score: +10.62

MFI Screen

Report this Post Reply

Featured Broker Partners


Advertisement